sorbitol has been researched along with Obesity in 31 studies
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, sorbitol levels were estimated in the cataractous lenses of the obese rats." | 7.78 | Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats. ( Giridharan, NV; Reddy, GB; Reddy, PY, 2012) |
| "Obesity is a global health problem associated with several diseases including ocular complications." | 5.56 | Role of sorbitol-mediated cellular stress response in obesity-associated retinal degeneration. ( Ayyagari, R; Godisela, KK; Kumar, CU; Reddy, GB; Reddy, PY; Reddy, SS; Reddy, VS, 2020) |
| "To clarify the effects and mechanisms of midodrine, an α1-adrenergic receptor agonist, in cataracts induced by obesity, we conducted various analytic experiments in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a rat model of obesity." | 4.12 | Stimulation of Alpha-1-Adrenergic Receptor Ameliorates Obesity-Induced Cataracts by Activating Glycolysis and Inhibiting Cataract-Inducing Factors. ( Eom, Y; Han, YM; Jang, YN; Jeong, JH; Jung, TW; Kim, HM; Lee, YJ; Seo, HS; Song, JS, 2022) |
| "SGL5213 and miglitol improved obesity, liver dysfunction, insulin resistance, and the NAFLD severity." | 4.02 | Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice. ( Honda, Y; Imajo, K; Iwaki, M; Kessoku, T; Kobayashi, T; Nagashima, Y; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Tomeno, W; Yoneda, M, 2021) |
| "Experiments were carried out to investigate whether diuretics (hydrochlorothiazide + furosemide) impact on the effects of a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor on glucose metabolism and blood pressure (BP) in metabolic syndrome SHR/NDmcr-cp(+/+) rats (SHRcp)." | 3.83 | Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. ( Fujisawa, Y; Hitomi, H; Kittikulsuth, W; Nakano, D; Nishiyama, A; Rafiq, K; Rahman, A; Sohara, E; Sufiun, A; Uchida, S, 2016) |
| "In this observational study, fasting glucose, sorbitol and fructose concentrations were measured using gas-chromatography-liquid mass spectroscopy in cerebrospinal fluid (CSF), maternal plasma, and venous cord blood collected from 25 pregnant women (6 lean, 10 overweight/obese, and 9 T2DM/gestational DM) undergoing spinal anesthesia and elective cesarean section." | 3.81 | Fructose levels are markedly elevated in cerebrospinal fluid compared to plasma in pregnant women. ( Belfort-DeAguiar, R; Cline, G; Han, CS; Hwang, JJ; Johnson, A; Khokhar, B; Sherwin, RS; Snegovskikh, D, 2015) |
| " In addition, sorbitol levels were estimated in the cataractous lenses of the obese rats." | 3.78 | Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats. ( Giridharan, NV; Reddy, GB; Reddy, PY, 2012) |
| "Utilisation of glucose and sorbitol in medically induced hypercorticalic states was investigated by means of the steroid-glucose-tolerance-test (SGTT) in 9 children, aged 6-16 years suffering from obesity and prediabetes." | 3.66 | [Varying utilization of glucose and sorbitol in drug-induced hypercortical metabolism]. ( Heine, W; Krüger, G; Said, M, 1982) |
| " The primary objective was to examine the dose-response relationship of licogliflozin treatment in body weight reduction relative to placebo at 12 weeks." | 2.94 | Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity. ( Keefe, D; Sano, M; Tsumiyama, I; Yokote, K, 2020) |
| "This dose-response analysis evaluated change in body weight following 24 weeks with four once-daily and twice-daily licogliflozin doses (2." | 2.94 | Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. ( Bays, HE; Keefe, D; Kozlovski, P; Proot, P; Shao, Q, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (41.94) | 18.7374 |
| 1990's | 3 (9.68) | 18.2507 |
| 2000's | 2 (6.45) | 29.6817 |
| 2010's | 8 (25.81) | 24.3611 |
| 2020's | 5 (16.13) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, YJ | 1 |
| Jang, YN | 1 |
| Kim, HM | 1 |
| Han, YM | 1 |
| Seo, HS | 1 |
| Eom, Y | 1 |
| Song, JS | 1 |
| Jeong, JH | 1 |
| Jung, TW | 1 |
| Mori, Y | 1 |
| Terasaki, M | 1 |
| Hiromura, M | 1 |
| Saito, T | 1 |
| Kushima, H | 1 |
| Koshibu, M | 1 |
| Osaka, N | 1 |
| Ohara, M | 1 |
| Fukui, T | 1 |
| Ohtaki, H | 1 |
| Tsutomu, H | 1 |
| Yamagishi, SI | 1 |
| Godisela, KK | 1 |
| Reddy, SS | 1 |
| Reddy, PY | 3 |
| Kumar, CU | 1 |
| Reddy, VS | 1 |
| Ayyagari, R | 1 |
| Reddy, GB | 3 |
| Yokote, K | 1 |
| Sano, M | 1 |
| Tsumiyama, I | 1 |
| Keefe, D | 2 |
| Bays, HE | 1 |
| Kozlovski, P | 1 |
| Shao, Q | 1 |
| Proot, P | 1 |
| Honda, Y | 1 |
| Ozaki, A | 1 |
| Iwaki, M | 1 |
| Kobayashi, T | 1 |
| Nogami, A | 1 |
| Kessoku, T | 1 |
| Ogawa, Y | 1 |
| Tomeno, W | 1 |
| Imajo, K | 1 |
| Yoneda, M | 1 |
| Saito, S | 1 |
| Nagashima, Y | 1 |
| Nakajima, A | 1 |
| Giridharan, NV | 2 |
| Balakrishna, N | 1 |
| Validandi, V | 1 |
| Pullakhandam, R | 1 |
| Hwang, JJ | 1 |
| Johnson, A | 1 |
| Cline, G | 1 |
| Belfort-DeAguiar, R | 1 |
| Snegovskikh, D | 1 |
| Khokhar, B | 1 |
| Han, CS | 1 |
| Sherwin, RS | 1 |
| Giesbertz, P | 1 |
| Padberg, I | 1 |
| Rein, D | 1 |
| Ecker, J | 1 |
| Höfle, AS | 1 |
| Spanier, B | 1 |
| Daniel, H | 1 |
| Okauchi, S | 1 |
| Shimoda, M | 1 |
| Obata, A | 1 |
| Kimura, T | 1 |
| Hirukawa, H | 1 |
| Kohara, K | 1 |
| Mune, T | 1 |
| Kaku, K | 1 |
| Kaneto, H | 1 |
| Rahman, A | 1 |
| Kittikulsuth, W | 1 |
| Fujisawa, Y | 1 |
| Sufiun, A | 1 |
| Rafiq, K | 1 |
| Hitomi, H | 1 |
| Nakano, D | 1 |
| Sohara, E | 1 |
| Uchida, S | 1 |
| Nishiyama, A | 1 |
| Gugliucci, A | 1 |
| Li, X | 1 |
| Hu, J | 1 |
| Zhang, R | 1 |
| Sun, X | 1 |
| Zhang, Q | 1 |
| Guan, X | 1 |
| Chen, J | 1 |
| Zhu, Q | 1 |
| Li, S | 1 |
| Howard, BV | 1 |
| Wylie-Rosett, J | 1 |
| Uccella, R | 1 |
| Morenghi, R | 1 |
| Agosti, C | 1 |
| Saponati, G | 1 |
| Heine, W | 1 |
| Krüger, G | 1 |
| Said, M | 1 |
| Dayhaw-Barker, P | 1 |
| Grühn, E | 1 |
| Elmadfa, I | 1 |
| Brunzell, JD | 1 |
| Magnati, G | 1 |
| Bandini, L | 1 |
| Pugnoli, C | 1 |
| Strata, A | 1 |
| Tirelli, F | 1 |
| Zuliani, U | 1 |
| Ditschuneit, HH | 1 |
| Schmidt, W | 1 |
| Ditschuneit, H | 1 |
| Berg, G | 1 |
| Matzkies, F | 1 |
| Huth, K | 1 |
| Jost, G | 1 |
| Schmahl, FW | 1 |
| Heckers, H | 1 |
| Dudeck, J | 1 |
| McCaleb, ML | 1 |
| Sredy, J | 1 |
| Schaffer, SW | 1 |
| Vicario, PP | 1 |
| Slater, EE | 1 |
| Saperstein, R | 1 |
| Mann, J | 1 |
| Fiser, RH | 1 |
| Matschinsky, FM | 1 |
| Ellerman, JE | 1 |
| Englhardt, A | 1 |
| Kasperek, R | 1 |
| Liebermeister, H | 1 |
| Jahnke, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 12 Weeks Treatment With 4 Doses of LIK066 Compared to Placebo in Japanese Patients With Obesity Disease[NCT03320941] | Phase 2 | 126 participants (Actual) | Interventional | 2017-12-07 | Completed | ||
| Influence of Food Liking of Adding Spices to Replace Dietary Sugar Using Sequential Monadic CLT Methodology[NCT03139552] | 150 participants (Actual) | Interventional | 2016-10-17 | Completed | |||
| Influence on Food Liking of Adding Spices to Replace Dietary Sugar[NCT03134079] | 160 participants (Actual) | Interventional | 2015-09-10 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The dose-response relationship of LIK066 as measured by percent change from baseline in body weight relative to placebo after 12 weeks of treatment. (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percent Change (Number) |
|---|---|
| LIK066 2.5mg qd | -1.86 |
| LIK066 10mg qd | -2.84 |
| LIK066 25 mg qd | -3.41 |
| LIK066 50 mg qd | -3.80 |
| Placebo | 0.11 |
Plasma trough concentrations of LIK066 were measured at Week 12 after daily administrations of LIK066 (2.5, 10, 25 and 50 mg). (NCT03320941)
Timeframe: Week 12
| Intervention | ng/mL (Mean) |
|---|---|
| LIK066 2.5mg qd | 1.63 |
| LIK066 10mg qd | 4.17 |
| LIK066 25 mg qd | 12.8 |
| LIK066 50 mg qd | 26.4 |
After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, DBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -3.54 | -4.40 | -2.45 |
| LIK066 2.5mg qd | -3.72 | -3.32 | -4.00 |
| LIK066 25 mg qd | -4.36 | -2.46 | -5.98 |
| LIK066 50 mg qd | -5.23 | -4.25 | -5.92 |
| Placebo | -3.12 | -4.31 | -1.93 |
FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake) at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mmol/L (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -0.665 | -0.126 | -1.111 |
| LIK066 2.5mg qd | -0.334 | 0.002 | -0.606 |
| LIK066 25 mg qd | -0.747 | -0.262 | -1.145 |
| LIK066 50 mg qd | -0.986 | -0.472 | -1.377 |
| Placebo | -0.160 | -0.217 | -0.079 |
After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -5.12 | -7.10 | -2.96 |
| LIK066 2.5mg qd | -4.90 | -5.79 | -4.16 |
| LIK066 25 mg qd | -6.36 | -3.58 | -8.63 |
| LIK066 50 mg qd | -6.94 | -4.17 | -9.00 |
| Placebo | -5.36 | -7.09 | -3.77 |
Waist circumference will be measured to the nearest 0.1 cm in a standing position, at the end of a normal expiration, using a tape at the level of umbilicus. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | cm (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.63 | -4.49 | -1.39 |
| LIK066 2.5mg qd | -2.47 | -2.78 | -2.22 |
| LIK066 25 mg qd | -2.65 | -2.08 | -2.90 |
| LIK066 50 mg qd | -3.11 | -2.23 | -3.88 |
| Placebo | -1.37 | -0.41 | -2.19 |
Uric acid will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | μmol/L (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -55.2 | -74.0 | -39.7 |
| LIK066 2.5mg qd | -52.6 | -74.9 | -34.1 |
| LIK066 25 mg qd | -58.4 | -69.1 | -48.4 |
| LIK066 50 mg qd | -62.0 | -72.9 | -51.6 |
| Placebo | 12.4 | 12.0 | 13.4 |
Urine albumin will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | x 10^4 mmol/L (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | 0.008 | 2.030 | -1.051 |
| LIK066 2.5mg qd | -1.838 | -1.941 | -3.899 |
| LIK066 25 mg qd | -3.902 | -2.456 | -3.605 |
| LIK066 50 mg qd | -3.099 | -3.406 | -2.165 |
| Placebo | -1.282 | -3.611 | -0.174 |
Urine albumin to creatinine ratio will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mg/mmol (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -0.848 | 0.487 | -1.863 |
| LIK066 2.5mg qd | -0.849 | -0.553 | -1.234 |
| LIK066 25 mg qd | -2.552 | -0.771 | -4.005 |
| LIK066 50 mg qd | -1.878 | -1.018 | -2.631 |
| Placebo | -1.504 | -1.122 | -1.839 |
High sensitivity CRP will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | 69.004 | 6.593 | 113.169 |
| LIK066 2.5mg qd | -48.448 | 16.582 | -89.337 |
| LIK066 25 mg qd | -24.207 | -36.745 | -18.143 |
| LIK066 50 mg qd | -55.536 | -43.562 | -71.025 |
| Placebo | -93.268 | -6.298 | -174.159 |
SFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -4.454 | -5.962 | -3.646 |
| LIK066 2.5mg qd | -6.562 | -7.745 | -5.457 |
| LIK066 25 mg qd | -7.983 | -7.234 | -8.415 |
| LIK066 50 mg qd | -5.745 | -2.127 | -8.481 |
| Placebo | -3.477 | -4.328 | -2.821 |
VFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percent (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -5.832 | -6.438 | -5.934 |
| LIK066 2.5mg qd | -4.139 | -1.532 | -6.461 |
| LIK066 25 mg qd | -9.185 | -5.977 | -12.916 |
| LIK066 50 mg qd | -11.352 | -7.333 | -14.728 |
| Placebo | -3.949 | -0.390 | -7.137 |
Fasting lipid profile (HDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.461 | 0.329 | -4.696 |
| LIK066 2.5mg qd | 1.499 | -0.519 | 2.886 |
| LIK066 25 mg qd | -5.253 | -3.279 | -6.993 |
| LIK066 50 mg qd | 0.112 | -0.147 | 0.235 |
| Placebo | -3.454 | -4.329 | -2.677 |
Fasting lipid profile (LDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.363 | -4.473 | -1.562 |
| LIK066 2.5mg qd | 0.757 | -3.065 | 3.727 |
| LIK066 25 mg qd | 0.037 | 2.579 | -1.295 |
| LIK066 50 mg qd | 4.726 | 2.128 | 6.803 |
| Placebo | -0.552 | -3.994 | 2.942 |
Fasting lipid profile (total cholesterol), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.983 | -6.017 | -1.367 |
| LIK066 2.5mg qd | -1.290 | -3.055 | 0.158 |
| LIK066 25 mg qd | 0.884 | 4.273 | -1.646 |
| LIK066 50 mg qd | 0.302 | -1.734 | 1.817 |
| Placebo | -2.244 | -3.559 | -0.671 |
Fasting lipid profile (Triglycerides (TG)), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | 11.057 | -1.986 | 23.108 |
| LIK066 2.5mg qd | 1.840 | -1.153 | 1.016 |
| LIK066 25 mg qd | 43.928 | 52.284 | 34.747 |
| LIK066 50 mg qd | 5.307 | 14.061 | -0.057 |
| Placebo | 17.401 | 20.962 | 13.806 |
HbA1c will be measured from a blood sample obtained and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -0.355 | -0.184 | -0.491 |
| LIK066 2.5mg qd | -0.285 | -0.139 | -0.405 |
| LIK066 25 mg qd | -0.366 | -0.196 | -0.502 |
| LIK066 50 mg qd | -0.418 | -0.163 | -0.618 |
| Placebo | -0.079 | -0.050 | -0.093 |
The dose-response relationship for weight loss in dysglycemic participants and participants with T2DM. Percentage change from baseline in body weight at Week 12. (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | percentage change (Number) | |
|---|---|---|
| Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.95 | -2.66 |
| LIK066 2.5mg qd | -1.90 | -1.64 |
| LIK066 25 mg qd | -3.29 | -3.42 |
| LIK066 50 mg qd | -3.47 | -4.23 |
| Placebo | 0.00 | 0.10 |
The responder rates according to percentage decrease in body weight either ≥ 3%, ≥ 5% or ≥ 10%, from baseline at Week 12, for the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 No Statistical Analysis for >=5% and >=10% was not calculated due to division by zero (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage of Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| >= 3% | >= 5% | >= 10% | >= 3% (Dysglycemic) | >= 5% (Dysglycemic) | >= 10% (Dysglycemic) | >= 3% (T2DM) | >= 5% (T2DM) | >= 10% (T2DM) | |
| LIK066 10mg qd | 55.6 | 27.8 | 0.0 | 75.0 | 62.5 | 0.0 | 40.0 | 0.00 | 0.00 |
| LIK066 2.5mg qd | 15.8 | 5.3 | 0.0 | 12.5 | 0.0 | 0.0 | 18.2 | 9.1 | 0.00 |
| LIK066 25 mg qd | 50.0 | 17.9 | 0.0 | 38.5 | 23.1 | 0.0 | 60.0 | 13.3 | 0.00 |
| LIK066 50 mg qd | 56.7 | 26.7 | 3.3 | 46.2 | 23.1 | 0.0 | 64.7 | 29.4 | 5.9 |
| Placebo | 7.1 | 0.0 | 0.0 | 7.7 | 0.0 | 0.0 | 6.7 | 0.00 | 0.00 |
Overall liking of apple crisp with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: Day of taste testing
| Intervention | score on likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 7.31 |
| Reduced Sugar Recipe | 6.83 |
| Reduced Sugar Plus Spice Recipe | 7.22 |
Overall liking of oatmeal with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: day of taste testing
| Intervention | score on a likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 6.84 |
| Reduced Sugar Recipe | 5.70 |
| Reduced Sugar Plus Spice Recipe | 6.15 |
Overall liking of tea with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: day of taste testing
| Intervention | score on a likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 6.00 |
| Reduced Sugar Recipe | 5.62 |
| Reduced Sugar Plus Spice Recipe | 5.85 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 54 |
| Second Place Ranking | 63 |
| Third Place Ranking | 33 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 88 |
| Second Place Ranking | 39 |
| Third Place Ranking | 21 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 66 |
| Second Place Ranking | 41 |
| Third Place Ranking | 42 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 48 |
| Second Place Ranking | 60 |
| Third Place Ranking | 40 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 63 |
| Second Place Ranking | 44 |
| Third Place Ranking | 43 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 49 |
| Second Place Ranking | 50 |
| Third Place Ranking | 50 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 33 |
| Second Place Ranking | 43 |
| Third Place Ranking | 74 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 12 |
| Second Place Ranking | 49 |
| Third Place Ranking | 87 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: Day of taste testings
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 34 |
| Second Place Ranking | 58 |
| Third Place Ranking | 57 |
5 reviews available for sorbitol and Obesity
| Article | Year |
|---|---|
Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases.
Topics: Adenosine Triphosphate; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructose; Glycat | 2017 |
Mechanisms of pathogenesis in diabetes mellitus.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Histocompatibilit | 1995 |
Use of fructose, sorbitol, or xylitol as a sweetener in diabetes mellitus.
Topics: Arteriosclerosis; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Dietary Carbohydrates; D | 1978 |
Cardiomyopathy associated with noninsulin-dependent diabetes.
Topics: Animals; Animals, Newborn; Calcium; Cardiomyopathies; Carrier Proteins; Diabetes Mellitus, Experimen | 1991 |
Dietary advice for diabetics: a perspective from the United Kingdom.
Topics: Blood Glucose; Diabetes Mellitus; Diabetic Angiopathies; Diet, Sodium-Restricted; Dietary Carbohydra | 1986 |
3 trials available for sorbitol and Obesity
| Article | Year |
|---|---|
Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Topics: Adult; Anhydrides; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Human | 2020 |
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Topics: Adolescent; Adult; Aged; Anhydrides; Body Weight; Double-Blind Method; Female; Humans; Male; Middle | 2020 |
[Serum lipoproteids and ketone bodies after constant infusion of sorbitol i.v. (author's transl)].
Topics: Acetoacetates; Dose-Response Relationship, Drug; Glycerophosphates; Gout; Humans; Hydroxybutyrates; | 1975 |
23 other studies available for sorbitol and Obesity
| Article | Year |
|---|---|
Stimulation of Alpha-1-Adrenergic Receptor Ameliorates Obesity-Induced Cataracts by Activating Glycolysis and Inhibiting Cataract-Inducing Factors.
Topics: Animals; Cataract; Glycolysis; Midodrine; Obesity; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Recep | 2022 |
Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling.
Topics: Adiponectin; Adipose Tissue; Adiposity; Animals; Diet, High-Fat; Disease Models, Animal; Femoral Art | 2019 |
Role of sorbitol-mediated cellular stress response in obesity-associated retinal degeneration.
Topics: Animals; Apoptosis; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Obesity; Rats; Receptor, | 2020 |
Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
Topics: 1-Deoxynojirimycin; Animals; Chronic Disease; Diet, High-Fat; Dietary Sucrose; Disease Models, Anima | 2021 |
Increased risk of cataract development in WNIN-obese rats due to accumulation of intralenticular sorbitol.
Topics: Animals; Cataract; Crystallins; Diabetes Mellitus, Experimental; Galactose; Glucose; Hot Temperature | 2013 |
Fructose levels are markedly elevated in cerebrospinal fluid compared to plasma in pregnant women.
Topics: Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fructose | 2015 |
Metabolite profiling in plasma and tissues of ob/ob and db/db mice identifies novel markers of obesity and type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Fatty Acids; Gas Chromato | 2015 |
Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
Topics: Animals; Apoptosis; Cell Proliferation; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2016 |
Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.
Topics: Administration, Oral; Animals; Blood Pressure; Diuretics; Furosemide; Hydrochlorothiazide; Hypertens | 2016 |
Urocortin ameliorates diabetic nephropathy in obese db/db mice.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cell Line; Connective Tissue Growth Factor | 2008 |
Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats.
Topics: Age Factors; Animals; Antioxidants; Cataract; Disease Models, Animal; Disease Susceptibility; Eye Pr | 2012 |
Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Diet; Dietary Sucrose; Fructose; Glyca | 2002 |
Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Diet; Dietary Sucrose; Fructose; Glyca | 2002 |
Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Diet; Dietary Sucrose; Fructose; Glyca | 2002 |
Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Diet; Dietary Sucrose; Fructose; Glyca | 2002 |
Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate).
Topics: Adult; Cholesterol; Glucagon; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Ma | 1983 |
[Varying utilization of glucose and sorbitol in drug-induced hypercortical metabolism].
Topics: Adolescent; Adrenocortical Hyperfunction; Child; Glucose; Glucose Tolerance Test; Glycosuria; Humans | 1982 |
[Nutrition physiology and pathology. Plant fibers in nutrition (proceedings)].
Topics: Aspartate Aminotransferases; Cachexia; Cholesterol; Constipation; Dietary Fiber; Energy Metabolism; | 1979 |
[Antilipolytic activity of Sorbinicato. Clinical-pharmacological study].
Topics: Adult; Fasting; Humans; Hypolipidemic Agents; Middle Aged; Nicotinic Acids; Obesity; Placebos; Sorbi | 1978 |
[Comparative studies on the effect of glucose and sorbitol on the reactive increase in insulin in obesity].
Topics: Female; Glucose; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Sorbitol | 1976 |
[Effect of various sugars on carbohydrate and lipid-metabolism parameters in normal and overweight patients].
Topics: Dietary Carbohydrates; Fructose; Glucose; Humans; Lipid Metabolism; Obesity; Sorbitol; Sucrose | 1975 |
Metabolic abnormalities of the hyperglycemic obese Zucker rat.
Topics: Animals; Fructose; Glucose; Glycosuria; Hyperglycemia; Inositol; Male; Obesity; Rats; Rats, Zucker; | 1992 |
The effect of ponalrestat on sorbitol levels in the lens of obese and diabetic mice.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Insu | 1989 |
Lipid metabolism, the polyol pathway and vascular complications.
Topics: Diabetes Mellitus; Diabetic Angiopathies; Female; Glucose; Humans; Infant, Newborn; Infant, Newborn, | 1973 |
Metabolism of glucose in the islets of Langerhans.
Topics: Acetone; Adenosine Triphosphate; Animals; Blood Glucose; Fluorometry; Glucose; Glycogen; Hexosephosp | 1968 |
Studies on glucose utilization and insulin responsiveness of human subcutaneous adipose tissue in obese and non-obese subjects.
Topics: Abdomen; Adipose Tissue; Adult; Age Factors; Animals; Blood; Body Water; Carbon Dioxide; Carbon Isot | 1971 |